Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.42 |
| ▸ | UGCG | Q16739 | 14/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791812 | 0.90 | GHSR (0.43) | GHSRUGCGCYP3A4TACR1 | |
| SCHEMBL6634185 | 0.90 | GHSR (0.43) | GHSRUGCGCYP3A4TACR1 | |
| SCHEMBL6633620 | 0.89 | GHSR (0.45) | GHSRUGCGCYP3A4 | |
| SCHEMBL7597562 | 0.88 | GHSR (0.42) | GHSRUGCGCYP3A4 | |
| SCHEMBL6633523 | 0.88 | GHSR (0.43) | GHSRUGCGCYP3A4 | |
| SCHEMBL5230927 | 0.87 | GHSR (0.45) | GHSRUGCGCYP3A4 | |
| SCHEMBL5228589 | 0.87 | GHSR (0.45) | GHSRUGCGCYP3A4 | |
| SCHEMBL3840114 | 0.84 | GHSR (0.55) | GHSRUGCGCYP3A4 | |
| SCHEMBL5224961 | 0.84 | GHSR (0.55) | GHSRUGCGCYP3A4 | |
| SCHEMBL7595422 | 0.84 | UGCG (0.45) | GHSRUGCGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995748-B1 | Growth hormone secretagogues | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6686359-B2 | ANIMAL GROWTH REGULATORS; OSTEOPOROSIS; CONGESTIVE HEART FAILURE; MUSCULAR DISORDERS | PFIZER INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030130284-A1 | Growth hormone secretagogues | CARPINO PHILIP A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6559150-B2 | Neurotransmitter stimulants; antidiabetic agents; congestive heart failure; obesity; frailty; maintaining renal and catabolic homeostasis; bone fracture repair; reducing cachexia and protein loss; muscle strength and burns. | PFIZER INC. | 2003-05-06 | — | — | US | disclosed |
| US-6358951-B1 | ADMINISTERING PYRAZOLO(4,3-C)PYRIDINE DERIVATIVE TO TREAT OBESITY, CONGESTIVE HEART FAILURE, OSTEOPOROSIS, AGING, BONE AND MUSCULAR DISORDERS | PFIZER INC. | 2002-03-19 | — | — | US | disclosed |
| EP-0995748-A1 | Growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130284-A1 | Growth hormone secretagogues | GHSR, GHRHR, GIPR | GHSR 1/4885UGCG 1631/4885CYP3A4 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.